Limerick BioPharma Gains $15M

South San Francisco-based Limerick BioPharma reported today that it has raised $15M in a Series C funding round. The round was led by OVP Venture Partners, and also included prior investors ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds. LImerick BioPharma is developing compounds to improve drug side effect profiles and clinical outcomes, specifically reducing toxicity of drugs on non-targeted organs and tissues. Chad Waite of OVP joins the firm's board as part of the funding. More information »